Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
Psoriasis is a chronic inflammatory skin disease. Metabolic syndrome is composed of obesity, hyperglycemia, hypertension and dyslipidemia. Previous reports have shown higher prevalence of metabolic syndrome in patients with psoriasis. It is believed that similar inflammatory changes lie in the pathophysiological background of psoriasis and metabolic syndrome. The main objective of this study was to assess the prevalence of metabolic syndrome and its components in patients with psoriasis, as well as to investigate the presence of systemic signs of inflammation such as erythrocyte sedimentation rate and C-reactive protein. The study included 60 patients with psoriasis and the same number of control subjects. We measured anthropometric and laboratory parameters; metabolic syndrome was defined according to the National Cholesterol Education Program-Adult Treatment Panel III criteria and Psoriasis Area and Severity Index was determined in all patients with psoriasis. This study showed a statistically significant presence of obesity (48.3%) and hyperglycemia (23.3%) in patients with psoriasis, while the prevalence of metabolic syndrome was 46.7%. These findings should encourage practitioners to screen psoriasis patients, especially when the disease is severe, for metabolic disorders and introduce appropriate prevention strategies.Psorijaza je kronična upalna kožna bolest. Metabolički sindrom se sastoji od pretilosti, hiperglikemije, hipertenzije i dislipidemije. U prethodnim istraživanjima uočena je povećana učestalost metaboličkog sindroma u bolesnika s psorijazom. Smatra se da su u patofiziološkoj podlozi psorijaze i metaboličkog sindroma slične upalne promjene. Glavni cilj istraživanja je bio utvrditi učestalost metaboličkog sindroma i njegovih sastavnica u oboljelih od psorijaze, kao i ispitati prisutnost sistemskih znakova upale, sedimentacije i C-reaktivnog proteina. Istraživanje je uključilo 60 bolesnika s psorijazom i jednak broj bolesnika ispitne skupine. Određeni su antropometrijski i laboratorijski parametri, dijagnoza metaboličkog sindroma je postavljena na osnovi kriterija koje je definirao NCEP-ATP III (National Cholesterol Education Program-Adult Treatment Panel III), a PASI indeks (Psoriasis Area and Severity Index) je određen svim bolesnicima s psorijazom. Istraživanje je pokazalo statistički značajno učestaliju pretilost (48,3%) i hiperglikemiju (23,3%) u skupini bolesnika s psorijazom, a učestalost metaboličkog sindroma iznosila je 46,7%. Ovi rezultati trebali bi liječnike potaknuti na probir bolesnika s psorijazom, naročito onih s teškim oblikom bolesti, na metaboličke poremećaje i uvođenje odgovarajuće prevencije
